Track cost pressure
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
BNF presentation directory
Explore British National Formulary presentations, drill into dispensing trend data, and identify which pharmacies drive the greatest usage of each medicine.
| Presentation | Product | Chemical substance | Chapter | Items dispensed |
|---|---|---|---|---|
|
Equasym 5mg tablets
0404000M0BCAAAJ
|
Equasym | Methylphenidate hydrochloride | Central Nervous System | No data available |
|
Equazen Baby oral liquid in capsules for opening
091200000BGAEGA
|
Equazen | Other health supplement preparations | Nutrition and Blood | No data available |
|
Equazen capsules
091200000BGAAFV
|
Equazen | Other health supplement preparations | Nutrition and Blood | No data available |
|
Equazen chews chewable capsules
091200000BGABFW
|
Equazen | Other health supplement preparations | Nutrition and Blood | No data available |
|
Equazen triple strength capsules
091200000BGADFY
|
Equazen | Other health supplement preparations | Nutrition and Blood | No data available |
|
Equilon 135mg tablets
0102000P0BFAAAB
|
Equilon | Mebeverine hydrochloride | Gastro-Intestinal System | No data available |
|
Equilon Herbal 0.2ml gastro-resistant capsules
0102000T0BGAAAA
|
Equilon Herbal | Peppermint oil | Gastro-Intestinal System | No data available |
|
Erastig 4.6mg/24hours transdermal patches
0411000E0BFAAAF
|
Erastig | Rivastigmine | Central Nervous System | No data available |
|
Erastig 9.5mg/24hours transdermal patches
0411000E0BFABAG
|
Erastig | Rivastigmine | Central Nervous System | No data available |
|
Erbitux 100mg/20ml solution for infusion vials
0801050AGBBABAB
|
Erbitux | Cetuximab | Malignant Disease and Immunosuppression | No data available |
|
Erbitux 100mg/50ml solution for infusion vials
0801050AGBBAAAA
|
Erbitux | Cetuximab | Malignant Disease and Immunosuppression | No data available |
|
Erbitux 500mg/100ml solution for infusion vials
0801050AGBBACAC
|
Erbitux | Cetuximab | Malignant Disease and Immunosuppression | No data available |
|
ErectAssist set
21180000091
|
ErectAssist set | Erectile Dysfunction Devices | Appliances | No data available |
|
Erelzi 25mg/0.5ml solution for injection pre-filled syringes
1001030D0BDAAAD
|
Erelzi | Etanercept | Musculoskeletal and Joint Diseases | No data available |
|
Erelzi 50mg/1ml solution for injection pre-filled pens
1001030D0BDACAE
|
Erelzi | Etanercept | Musculoskeletal and Joint Diseases | No data available |
|
Erelzi 50mg/1ml solution for injection pre-filled syringes
1001030D0BDABAC
|
Erelzi | Etanercept | Musculoskeletal and Joint Diseases | No data available |
|
Erenumab 140mg/1ml inj pre-filled disposable devices
0407042T0AAABAB
|
Erenumab | Erenumab | Central Nervous System | No data available |
|
Erenumab 70mg/1ml inj pre-filled disposable devices
0407042T0AAAAAA
|
Erenumab | Erenumab | Central Nervous System | No data available |
|
Ergamisol 50mg tablets
0505020L0BCAAAB
|
Ergamisol | Levamisole hydrochloride | Infections | No data available |
|
Ergo-D2 12.5microgram tablets
0906040N0BWABEW
|
Ergo-D2 | Ergocalciferol | Nutrition and Blood | No data available |
|
Ergocalciferol 1,250units/5ml oral suspension
0906040N0AAEAEA
|
Ergocalciferol | Ergocalciferol | Nutrition and Blood | No data available |
|
Ergocalciferol 1,400units/5ml oral liquid
0906040N0AAELEL
|
Ergocalciferol | Ergocalciferol | Nutrition and Blood | No data available |
|
Ergocalciferol 1,500units/5ml oral suspension
0906040N0AADIDI
|
Ergocalciferol | Ergocalciferol | Nutrition and Blood | No data available |
|
Ergocalciferol 1,875units/5ml oral liquid
0906040N0AAEMEM
|
Ergocalciferol | Ergocalciferol | Nutrition and Blood | No data available |
|
Ergocalciferol 1,950units/5ml oral liquid
0906040N0AADYDY
|
Ergocalciferol | Ergocalciferol | Nutrition and Blood | No data available |
Why monitor BNF codes?
Link medicine usage to pharmacy and prescriber behaviour to find optimisation opportunities.
Understand demand drivers
Cross-reference high-volume medicines with local health priorities and prescriber activity to target support programs.